Irish company ICON has agreed to acquire contract research company PRA Health Sciences in a cash and stock deal valued at about $12bn.

The acquisition brings two organisations together with a shared focus on quality and efficient clinical trial execution from Phase I to post-approval studies.

ICON stated that all the biopharma and medical device customers will benefit from increased service offerings and geographic footprint, therapeutic expertise, expansive healthcare technology innovation, and functional talent and capabilities.

The combination of PRA’s mobile and connected health platforms and real-world data and information solutions together with ICON’s Accellacare site network, home health services and wearables expertise, will help meet the growing customer requirements for differentiated decentralised and hybrid trial solutions.

ICON CEO Dr Steve Cutler said: “Both ICON and PRA have track records of robust growth and performance and we are ready to build on this unrivalled position of strength, utilising the outstanding talent in both organisations.

“With broader and deeper operational scale combined with innovative technology and real world data solutions, we will enable all customers to reduce their development time and cost.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We will be the leading provider of de-centralised and hybrid trial solutions through the integration of our data capabilities, health platforms and Accellacare site network.”

For the deal, ICON will pay $80 in cash and 0.4125 shares of its stock to PRA shareholders.

Subject to regulatory and shareholder approvals and customary closing conditions, the transaction is expected to be concluded during the third quarter of this year.

Upon completion of the deal, ICON shareholders will own about 66% of the combined company’s shares and the remaining 34% stake will be with PRA shareholders.